       Document 0199
 DOCN  M95A0199
 TI    Treatment options for vulvovaginal candidiasis, 1993.
 DT    9510
 AU    Reef SE; Levine WC; McNeil MM; Fisher-Hoch S; Holmberg SD; Duerr A;
       Smith D; Sobel JD; Pinner RW; Centers for Disease Control and
       Prevention, Emerging Bacterial; and Mycotic Diseases Branch, Atlanta,
       Georgia 30333, USA.
 SO    Clin Infect Dis. 1995 Apr;20 Suppl 1:S80-90. Unique Identifier :
       AIDSLINE MED/95315416
 AB    Vulvovaginal candidiasis (VVC), the second most common form of
       vaginitis, particularly affects women of childbearing age. Since the
       1970s, several new agents have become available for the treatment of
       VVC. This review focuses on options for the treatment of this condition,
       critically evaluating the relevant published studies. For the treatment
       of acute episodes of VVC in nonpregnant women, several topical and oral
       antifungal agents are clinically and mycologically effective. Topical
       agents should be considered the first line of therapy; however, oral
       agents are sometimes associated with better compliance among patients.
       For acute episodes in pregnant women, a topical agent is the treatment
       of choice. Until data become available on the treatment of VVC in women
       infected with human immunodeficiency virus (HIV), the same approach as
       that used for women without HIV infection should be considered as
       previously written. For recurrent VVC, the optimal maintenance therapy
       has not yet been established; however, administration of low-dose oral
       ketoconazole (100 mg/d) has proven effective. Well-designed studies of
       the best therapy for VVC in women with HIV infection and for recurrent
       VVC are urgently needed.
 DE    Acute Disease  Administration, Oral  Administration, Topical
       Antibiotics/THERAPEUTIC USE  Candidiasis,
       Vulvovaginal/COMPLICATIONS/*DRUG THERAPY  Female  Human  HIV
       Infections/COMPLICATIONS  Pregnancy  Pregnancy Complications,
       Infectious/DRUG THERAPY  Recurrence  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

